Plain-English translation of NCT06272734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This pilot study is testing a new medical device called the Reprieve System designed to help people hospitalized with acute heart failure. The device delivers personalized combinations of diuretics (water pills) and saline solution to safely remove excess fluid from your body. Researchers want to see if this treatment approach can help you feel better and recover more effectively.
When your heart can't pump well, fluid builds up in your lungs and body, making it hard to breathe and causing swelling. Standard treatments don't always work the same way for everyone. This trial exists to see if a personalized approach using the new treatment can help doctors remove excess fluid more safely and effectively.
You likely qualify if…
You likely don't qualify if…
During your hospital stay, you will receive treatment using the Reprieve System, which delivers personalized diuretic and saline infusions through an IV line while monitoring your response carefully. The device adjusts your treatment based on how your body is responding to help safely remove excess fluid. You will have follow-up visits and monitoring to track how well the treatment works and check for any side effects.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Georgia
Sponsor
Reprieve Cardiovascular, Inc
Enrollment target
~50 participants
Started
January 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tony Fields
Tbilisi Heart and Vascular Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.